You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Biosense Webster – Health Economics & Outcomes Research
Biosense Webster, Inc. expands patient access to our advanced technologies by articulating the clinical and economic value associated with our innovative products through peer-review health economic modelling.
Treatment of Atrial Fibrillation Using Ablation Index- Guided Contact Force Ablation: A Matching-Adjusted Indirect Comparison to Cryoballoon Ablation
Compare the effectiveness of THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter with Ablation Index (STAI) on recurrence of atrial arrhythmias 12 months after catheter ablation to that of Arctic Front Advance™ (CB)
- Matching Adjusted Indirect Comparison
STAI: IPD from two prospective studies, Solimene et al. 2019 and Hussein et al. 2017.
Three CB studies were identified in a systematic literature review
When age, sex, and LVEF were adjusted, a significant 70% reduction in recurrence rate was associated with STAI when compared to CB (HR 0.30; 95% CI 0.13–0.71).
Comparative Effectiveness of Catheter Ablation Devices in the Treatment of Atrial Fibrillation: A Network Meta-analysis of Patients in Prospective Studies
Compare the effectiveness of THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter with Ablation Index/ SURPOINT™ (STAI) to other available catheters for AF ablation.
- Bayesian network meta-analysis
12 studies (1,722 patients) were identified in a systematic literature review
STAI was associated with were significantly higher freedom from atrial arrhythmias at 12 months
- 77% greater likelihood than Arctic Front
- 41% greater likelihood than Arctic Front Advance™
- 34% greater likelihood than THERMOCOOL™ Catheter
- 9% greater likelihood than THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter alone
Cost Minimization Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation by Catheter Technology
Evaluate the costs of AF ablation with the THERMOCOOL SMARTTOUCH® Catheter (ST), THERMOCOOL SMARTTOUCH® SF Catheter (SF) and Arctic Front Advance™ Cardiac Cryoablation Catheter (CB).
A decision tree model was developed to compare outcomes of simulated scenarios
Cost outcomes were compared between ablations using ST vs. SF, and ablations using ST vs. CB
Expected savings for ST compared to CB was $8,206 (inpatient), $3,859 (outpatient) and $4,494 (hospital mix)
Expected savings for ST compared to SF was $1,763 (inpatient), $1,405 (outpatient) and $1,488 (hospital mix)
The third-party trademarks used herein are the trademarks of the respective owners.